Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors - PubMed (original) (raw)

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors

N Boulle et al. J Clin Endocrinol Metab. 1998 May.

Abstract

In adrenocortical tumors, malignancy is strongly associated with insulin-like growth factor II (IGF-II) gene overexpression and abnormalities at the 11p15 locus, suggesting a role for this growth factor in adrenocortical tumorigenesis. To further investigate this role, the IGF/IGF-binding protein (IGFBP) system was analyzed in 18 adrenocortical tumors, classified into 2 groups on the basis of their IGF-II messenger ribonucleic acid (mRNA) content (group 1, normal IGF-II mRNA content, mostly benign tumors; group 2, high IGF-II mRNA content, mostly malignant tumors). Group 2 tumors contained 10 times more IGF-II protein than group 1 tumors or normal adrenal tissue (P < 0.001), indicating efficient translation of IGF-II mRNA in malignant tumors. Western ligand blotting detected various functional IGFBPs in normal adrenocortical glands and tumors: a doublet of 39-42 kDa identified by immunoblotting as IGFBP-3, a band at 32 kDa, and bands at 29-30 and 24 kDa. Total IGFBP-3 protein levels were similar in the two groups of tumors. By contrast, malignant tumors differed from benign ones by specific expression of the 32-kDa IGFBP. Immunoblotting identified this 32-kDa band together with a proteolytic fragment of 25 kDa as IGFBP-2, and quantitative analysis showed significantly higher levels of total IGFBP-2 in malignant tumors than in benign tumors (P < 0.001). Despite enhanced levels of IGBP-2 protein in malignant tumors, no increase in IGFBP-2 mRNA levels was detected, suggesting post-transcriptional regulation of this IGFBP. These results confirm the major role of IGF-II in adrenocortical tumorigenesis and suggest that IGFBP-2 may be a regulator of IGF-II proliferative effects in this tumor system.

PubMed Disclaimer

Cited by

The insulin and igf-I pathway in endocrine glands carcinogenesis.
Malaguarnera R, Morcavallo A, Belfiore A. Malaguarnera R, et al. J Oncol. 2012;2012:635614. doi: 10.1155/2012/635614. Epub 2012 Aug 8. J Oncol. 2012. PMID: 22927847 Free PMC article.
Adrenal cortical carcinoma.
Dackiw AP, Lee JE, Gagel RF, Evans DB. Dackiw AP, et al. World J Surg. 2001 Jul;25(7):914-26. doi: 10.1007/s00268-001-0030-7. World J Surg. 2001. PMID: 11572033 Review.
Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.
Degraff DJ, Aguiar AA, Sikes RA. Degraff DJ, et al. Am J Transl Res. 2009 Jan 20;1(2):115-30. Am J Transl Res. 2009. PMID: 19956425 Free PMC article.
Adrenocortical carcinoma: a clinician's update.
Fassnacht M, Libé R, Kroiss M, Allolio B. Fassnacht M, et al. Nat Rev Endocrinol. 2011 Jun;7(6):323-35. doi: 10.1038/nrendo.2010.235. Epub 2011 Mar 8. Nat Rev Endocrinol. 2011. PMID: 21386792 Review.
How to Differentiate Benign from Malignant Adrenocortical Tumors?
Viëtor CL, Creemers SG, van Kemenade FJ, van Ginhoven TM, Hofland LJ, Feelders RA. Viëtor CL, et al. Cancers (Basel). 2021 Aug 30;13(17):4383. doi: 10.3390/cancers13174383. Cancers (Basel). 2021. PMID: 34503194 Free PMC article. Review.

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors - PubMed (original) (raw)